Prothena Plc Company Insiders
| PRTA Stock | USD 10.40 0.08 0.76% |
Prothena Plc employs about 163 people. The company is managed by 14 executives with a total tenure of roughly 26 years, averaging almost 1.0 years of service per executive, having 11.64 employees per reported executive. Analysis of Prothena Plc's management performance can provide insight into the company performance.
| Wagner Zago Executive Chief Scientific Officer |
| Carol Karp Executive Chief Regulatory Officer |
Prothena Plc Management Team Effectiveness
The company has return on total asset (ROA) of (0.2931) % which means that it has lost $0.2931 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6763) %, meaning that it created substantial loss on money invested by shareholders. Prothena Plc's management efficiency ratios could be used to measure how well Prothena Plc manages its routine affairs as well as how well it operates its assets and liabilities.Prothena Plc Workforce Comparison
Prothena plc is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 28,169. Prothena Plc maintains roughly 163 in number of employees contributing less than 1% to equities under Health Care industry.
Prothena Plc Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prothena Plc insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prothena Plc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Prothena Plc insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Prothena Plc Notable Stakeholders
A Prothena Plc stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Prothena Plc often face trade-offs trying to please all of them. Prothena Plc's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Prothena Plc's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Hideki MD | Chief Officer | Profile | |
| CPA CPA | Chief Controller | Profile | |
| Jennifer Zibuda | Director Communication | Profile | |
| Brandon Smith | Chief Officer | Profile | |
| Wagner Zago | Chief Scientific Officer | Profile | |
| Carol Karp | Chief Regulatory Officer | Profile | |
| David Ford | Chief Officer | Profile | |
| Chad Swanson | Chief Officer | Profile | |
| Yvonne Tchrakian | Company Secretary | Profile | |
| Michael Malecek | Chief Secretary | Profile | |
| Mark CFA | Vice Relations | Profile | |
| Karin CPA | Chief Controller | Profile | |
| Tran MBA | CFO Officer | Profile | |
| Gene Kinney | Chief Scientific Officer and Head of RandD | Profile |
About Prothena Plc Management Performance
The success or failure of an entity such as Prothena plc often depends on how effective the management is. Prothena Plc management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Prothena management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Prothena management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company was founded in 2012 and is based in Dublin, Ireland. Prothena Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.
Please note, the presentation of Prothena Plc's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Prothena Plc's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Prothena Plc's management manipulating its earnings.
Prothena Plc Workforce Analysis
Traditionally, organizations such as Prothena Plc use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Prothena Plc within its industry.Prothena Plc Manpower Efficiency
Return on Prothena Plc Manpower
| Revenue Per Employee | 829.2K | |
| Revenue Per Executive | 9.7M | |
| Net Loss Per Employee | 750.4K | |
| Net Loss Per Executive | 8.7M | |
| Working Capital Per Employee | 2.7M | |
| Working Capital Per Executive | 31.2M |
Complementary Tools for Prothena Stock analysis
When running Prothena Plc's price analysis, check to measure Prothena Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prothena Plc is operating at the current time. Most of Prothena Plc's value examination focuses on studying past and present price action to predict the probability of Prothena Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prothena Plc's price. Additionally, you may evaluate how the addition of Prothena Plc to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |